This bioRxiv preprint from Dalhousie and Queen's University uses a post-entry reactivation model (doxycycline-induced KSHV in iSLK.219 and TREx-BCBL-RTA cells) to isolate effects of cholesterol perturbation on replication without confounding entry steps . Treatment with 9β10 Β΅M 22OH upregulated ABCA1, reduced total cellular cholesterol in lytic cells, and produced a ~10-fold drop in capsid-protected extracellular genomes in two KSHV models; cerivastatin (50 nM), an independent cholesterol-depletion route via HMGCR inhibition, gave a 4-fold infectivity reduction, supporting mechanism convergence rather than oxysterol off-targets alone. Deep DIA proteomics (~9,000 proteins quantified, 3 replicates/timepoint) showed broadly reduced late viral proteins (terminase ORF29/ORF67.5, capsid ORF62/ORF65, tegument ORF38/ORF42) at 72 h, while viral mRNAs were unchanged β pointing to a post-transcriptional bottleneck. TEM (>900 capsids/condition, 3 replicates) quantified a shift toward immature A/B capsids; HSV-2 pUL31/pUL34 failed to recruit to the nuclear periphery, extending the phenotype to alphaherpesviruses. Proteomics (PRIDE: PXD068855) revealed a non-classical antiviral state: type I IFN/inflammatory proteins mostly downregulated (STAT2, IL6ST, IFITM3), while OASL, HERC5, and SAA1 were upregulated.
Reported data: at 72 h, A-capsids rise from 23.6% to 35.6% and C-capsids fall under 22OH β a quantified signature of failed genome packaging/egress competency. Author interpretation: cholesterol efflux disrupts NEC function at the inner nuclear membrane, possibly via altered membrane fluidity or protein trafficking. BGPT inference: the capsid shift could also be downstream of reduced late-protein abundance rather than a direct membrane effect; these are not dissociated.
Strengths: triangulated evidence (qPCR, infectivity, proteomics, TEM, IF); two independent cholesterol-depletion strategies; replication across three herpesviruses; deposited data; sub-cytotoxic dosing with CC50 β 19 Β΅M; honest acknowledgment that 22OH enhances reactivation yet inhibits egress β a counterintuitive finding that strengthens the claim of a specific late-stage block. Weaknesses: (1) pharmacological 22OH has LXR-independent effects (SREBP suppression, membrane biophysics) not fully separated from ABCA1-mediated efflux β no ABCA1 knockdown or LXR antagonist control is reported; (2) TEM is 2D and non-stereological, acknowledged by the authors who added ORF65 cytoplasmic IF; (3) causal host factors (RIG-I regulation via SEC14L1/DHX58, OASL, HERC5) remain speculative; (4) all cell-line, in vitro work β no primary cells or in vivo validation; (5) HSV experiments use plaque assays in HeLa, a non-natural cell type for HSV-2 nuclear egress phenotypes. Falsification: the authors' own criteria β if ABCA1 is not induced, cholesterol unchanged, or NEC localization unaffected β remain untested but clearly stated. What would change the conclusion: rescue of egress by ABCA1 depletion or cholesterol re-loading under 22OH.
Cholesterol's role in herpesvirus entry and virion stability is established; the demonstration that efflux specifically impairs nuclear egress across alpha- and gammaherpesviruses is new, complementing prior work on methyl-Ξ²-cyclodextrin blocking secondary envelopment at the TGN. The link to nucleoplasmic reticulum (CCTΞ±) biology from the group's companion work is a plausible but unverified mechanistic thread.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.